EKF Diagnostics (LON:EKF) Announces Earnings Results

EKF Diagnostics (LON:EKF) released its earnings results on Tuesday. The company reported GBX 1.38 ($0.02) EPS for the quarter, Digital Look Earnings reports. EKF Diagnostics had a return on equity of 7.03% and a net margin of 9.37%.

EKF Diagnostics Stock Down 1.8 %

Shares of LON:EKF traded down GBX 0.40 ($0.01) on Thursday, hitting GBX 21.60 ($0.28). 3,655,892 shares of the company’s stock were exchanged, compared to its average volume of 566,477. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.77 and a current ratio of 4.60. EKF Diagnostics has a 1-year low of GBX 18.40 ($0.24) and a 1-year high of GBX 33.80 ($0.44). The company has a market capitalization of £96.01 million, a PE ratio of 20.10 and a beta of 0.57. The firm’s 50-day moving average is GBX 23.23 and its 200 day moving average is GBX 25.85.

Insider Buying and Selling

In other news, insider Gavin T. Jones acquired 50,000 shares of the company’s stock in a transaction on Tuesday, March 25th. The shares were bought at an average price of GBX 22 ($0.28) per share, with a total value of £11,000 ($14,162.48). 5.24% of the stock is owned by company insiders.

EKF Diagnostics Company Profile

EKF is an AIM-listed global diagnostics business focussed on:

● Point-of-Care analysers in the key areas of Hematology and Diabetes

● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.